Diagnostic reagent market has great potential for development in the future.

DETAILS

In recent years, with the increase of medical insurance investment and consumption level, the diagnostic reagent industry in China has entered a growing period, with a certain market scale. However, compared with the mature foreign markets, China's diagnostic reagent market has not been fully developed, there is still a great potential for development in the future. With the improvement of people's living standards and the reform of the national medical system, the market scale will inevitably be further expanded.

Development status of diagnostic reagents Industry

Diagnostic reagents are biological agents used to diagnose diseases, detect immune status and identify pathogenic microorganisms. Diagnostic reagents can be divided into two categories: in vivo diagnostic reagents and in vitro diagnostic reagents.

At present, the domestic market is mainly based on in vitro diagnostic reagents. In vitro diagnostic reagents are disposable consumables, compared with diagnostic instruments that generally have a life span of more than 5-8 years, so the real growth rate of the reagent market is faster than the overall in vitro diagnostic market.

Since 2006, the domestic diagnostic industry has been growing at a rate of about 15% annually. According to statistics, the market size of in vitro diagnosis in China has reached 9.5 billion yuan in 2008, increased to 12.2 billion yuan in 2010 and exceeded 20 billion yuan in 2013. By 2015, the market size of in vitro diagnosis in China is close to 31.6 billion yuan, of which the in vitro diagnostic reagent is about 24.1 billion yuan.

The scale of in vitro diagnostic reagents market in China in 2008-2015 years (unit: 100 million yuan)

From 2008 to 2015, the market of in vitro diagnostic reagents in China is mainly composed of biochemical, immunological and molecular diagnostic reagents, and the three kinds of reagents are growing rapidly. Among them, the growth rate of molecular diagnostic reagents is the highest, the annual compound growth rate can reach 20%, followed by immunodiagnostic reagents, the annual compound growth rate is 18%, and the annual compound growth rate of biochemical and other diagnostic reagents is the highest. The rate will reach 15%.

According to the comparison between the growth rate of in vitro diagnostic reagent and the whole industry in the past few years, it can be seen that the average annual growth rate of in vitro diagnostic reagent is 2-3 percentage points higher than that of the whole industry. Therefore, it is conservatively estimated that the growth rate of in vitro diagnostic reagent industry in the future will not be less than 19%. According to this growth rate, China's body will grow by 2022. The market scale of external diagnostic reagents will reach 81 billion 500 million yuan.

Trend analysis of diagnostic reagent industry

In terms of demand, after years of rapid development of the domestic clinical laboratory market, although some important clinical product projects have entered the mature stage, the domestic market development has slowed down, but still at the rate of 15% - 20%. Compared with hundreds of products in the world, the domestic market is far from being developed. Even from the current demand for a large number of mature diseases, the market still has great potential for development. At the same time, the demand for diagnostic reagents in various medical institutions is polarized: high-end hospitals require high-throughput, high-efficiency, high-sensitivity testing products, while grass-roots hospitals need fast, affordable, safe and efficient products.

In terms of products, the diagnostic reagent industry has the largest share of the early clinical chemical diagnosis market, but in recent years immunodiagnosis has gradually exceeded the share of clinical chemical diagnosis. Molecular diagnosis, as a newly developed technology, has the fastest development among all diagnostic types, mainly because of the deep expansion of human genome research. The research field of molecular diagnosis has promoted the development of laboratory medicine in disease diagnosis and prognosis evaluation. In addition, chemiluminescence diagnostic reagent is expected to become the mainstream product in the field of immune diagnosis in the future.

In terms of technology, the diagnostic reagent technology in China is developing toward two polarization: one is highly integrated and automated diagnostic instrument technology with high efficiency instruments and equipment, modular combination and automatic pipeline control, which greatly improves the efficiency of diagnostic testing; the other is simple, rapid and easy to popularize and realize. The diagnostic technology of field testing, which requires miniaturization of experimental instruments, simplification of operation, prompt and accurate report of results, is increasingly favored by clinical doctors and nurses.